Overview

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:
0

Participant gender:
All

Summary

This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Anidulafungin
Echinocandins
Voriconazole

Criteria

Inclusion Criteria:

- Immunocompromised state due to either 1. receipt of hematopoeitic stem cell
transplantation or 2. hematologic malignancy;

- Diagnosis of possible, probable, or proven invasive aspergillosis.

Exclusion Criteria:

- Patients with aspergilloma or chronic aspergillosis

- Receipt of 4 or more days of systemic antifungal treatment for the current episode of
invasive aspergillosis

- Anticipated survival of less than 5 days or Karnofsky score <=20